Eledon Pharmaceuticals, Inc. Deferred Federal Income Tax Expense (Benefit)
Eledon Pharmaceuticals, Inc. (ELDN) reported Deferred Federal Income Tax Expense (Benefit) of -$2.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2023-03-30
- Eledon Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2021 was -$2.75M.
- Eledon Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2020 was -$404.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | -$2.75M 10-K · filed 2023-03-30 |
| 2020-12-31 | -$404.00K 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |